Ryan Specialty Holdings, Inc. (RYAN) Stock Price & How to Invest

Ryan Specialty Holdings is an international specialty insurance intermediary founded by Patrick Ryan (who also founded Aon). It sits between retail insurance brokers and carriers, operating two core engines: wholesale brokerage (led by RT Specialty, one of the largest E&S and binding-authority platforms in the US) and underwriting management, where its managing general underwriters (MGUs) hold delegated authority from carriers to underwrite niche risks in areas like energy, healthcare, construction, and enterprise risk. It does not take underwriting risk on its own balance sheet; it earns commissions and fees for placing and structuring hard-to-place specialty coverage.

The investment picture is one of a fast-growing, acquisitive distributor riding the multi-year shift of business into the excess and surplus lines market, now meeting a softer pricing cycle. Revenue reached roughly $795 million in Q1 2026 (up about 15% year over year, with organic growth near 12%) and about $917 million in Q2 2026, its seasonally largest quarter, where total revenue growth slowed to about 7% year over year. Q2 net income was about $108 million and adjusted EPS of $0.74 beat the $0.60 consensus. Trailing-twelve-month revenue is about $3.2 billion. The company has partnered with 55-plus firms through acquisition since inception. The tension is cyclicality and leverage: management has flagged that pronounced property-rate declines and intensifying competition are pressuring organic growth and margins in 2026, and the company carries about $3.8 billion of debt against about $140 million of cash. As of October 16, 2026, the stock at $40.19 is down about 21% YTD and about 23% over one year, within a 52-week range of roughly $29 to $59. Third-quarter results are scheduled for October 29, 2026, with consensus EPS of about $0.49 on revenue near $793 million.

The biggest near-term risk is insurance-pricing cyclicality: management has pointed to pronounced property-rate declines and intensifying competition, guiding to mid-single-digit organic growth and a modest margin decline for the year, with one quarter guided near zero organic growth. Softer rates directly reduce commission-based revenue, and Q2 2026 revenue growth already slowed to about 7%. Reported profit is thin, with trailing net income of about $99 million (a 3% profit margin) because of amortization, interest, and acquisition-related costs, so the trailing P/E sits near 57x. Acquisition-heavy growth brings integration, goodwill, and leverage risk, and the company carries about $3.8 billion of debt. Analysts have been trimming price targets into the Q3 report. Finally, it depends on relationships with carriers for delegated underwriting capacity, which can tighten in a downturn, and it operates in a competitive field against larger and well-capitalized wholesalers.

16 analysts publish price targets on RYAN, averaging $49.09 against a $40.75 price as of October 2026, or +20.5%. The published targets run from $38.00 to $76.00, a wide spread, and the ratings split 9 buy, 9 hold, 1 sell. Over the last six months there have been 8 raises and 4 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full RYAN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Ryan Specialty Holdings, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. E&S market tailwind. Ryan Specialty is a leading intermediary in the excess and surplus lines market, which has grown for years as more complex, catastrophe-exposed, and hard-to-place risks flow out of the standard admitted market. The most optimistic published target, $76.00, assumes this works close to its best case.

The case against. The biggest near-term risk is insurance-pricing cyclicality: management has pointed to pronounced property-rate declines and intensifying competition, guiding to mid-single-digit organic growth and a modest margin decline for the year, with one quarter guided near zero organic growth. The most pessimistic target, $38.00, is roughly what RYAN is worth if this bites instead.

Read the full bull and bear case on RYAN, including what would have to change to break either one. Walnut is not an investment adviser.

No. Ryan Specialty Holdings, Inc. (RYAN) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Ryan Specialty Holdings, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$3.2B
• Q2 2026 revenue: ~$917M (up ~7% YoY)
• Operating margin (TTM): ~25%
• Net income (TTM): ~$99M
• Q2 2026 adj. EPS vs estimate: ~$0.74 vs ~$0.60
• P/E (trailing / forward): ~57x / ~16x
• Dividend yield: ~1.3%
• Market cap: ~$10.3B

At $40.19 on October 16, 2026, Ryan Specialty trades at about 57 times trailing reported earnings but only about 16 times forward earnings and about 10 times EV/EBITDA, cheaper than in July after a roughly 21% YTD decline. The gap between trailing and forward multiples reflects acquisition amortization and interest that hold down reported profit. Q3 results on October 29, 2026 will show whether organic growth is holding as property rates soften.

Other names that sit close to RYAN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get RYAN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so RYAN sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where RYAN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

RYAN is a growth-oriented play on specialty and E&S insurance distribution whose share price has de-rated in 2026, with property-rate softening, a heavy debt load, and integration risk as the main things to weigh against a forward P/E now near 16x.

Whether RYAN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is RYAN a buy or a sell?, and where the stock could go from here in the RYAN stock forecast.

For income investors, whether RYAN pays a dividend and how the payout looks is covered in does RYAN pay a dividend? And to weigh RYAN against a peer, read the full side-by-side comparisons: RYAN vs CRC and RYAN vs AJG.